We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $179.25, demonstrating a +1.26% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.6%. On the other hand, the Dow registered a gain of 0.83%, and the technology-centric Nasdaq increased by 0.64%.
Shares of the kidney dialysis provider witnessed a loss of 2.38% over the previous month, trailing the performance of the Medical sector with its loss of 1.97%, and the S&P 500's gain of 1.34%.
Market participants will be closely following the financial results of DaVita HealthCare in its upcoming release. The company's upcoming EPS is projected at $3.78, signifying a 50.60% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $3.53 billion, indicating a 3.23% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.57 per share and revenue of $14.28 billion. These totals would mark changes of +35.16% and +4.67%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 12.15. This signifies a discount in comparison to the average Forward P/E of 20.06 for its industry.
We can additionally observe that DVA currently boasts a PEG ratio of 0.46. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical - Outpatient and Home Healthcare industry stood at 1.78 at the close of the market yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 57, positioning it in the top 24% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $179.25, demonstrating a +1.26% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.6%. On the other hand, the Dow registered a gain of 0.83%, and the technology-centric Nasdaq increased by 0.64%.
Shares of the kidney dialysis provider witnessed a loss of 2.38% over the previous month, trailing the performance of the Medical sector with its loss of 1.97%, and the S&P 500's gain of 1.34%.
Market participants will be closely following the financial results of DaVita HealthCare in its upcoming release. The company's upcoming EPS is projected at $3.78, signifying a 50.60% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $3.53 billion, indicating a 3.23% upward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.57 per share and revenue of $14.28 billion. These totals would mark changes of +35.16% and +4.67%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Right now, DaVita HealthCare possesses a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is presently being traded at a Forward P/E ratio of 12.15. This signifies a discount in comparison to the average Forward P/E of 20.06 for its industry.
We can additionally observe that DVA currently boasts a PEG ratio of 0.46. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical - Outpatient and Home Healthcare industry stood at 1.78 at the close of the market yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 57, positioning it in the top 24% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.